Phase i trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 3, Issue 9, 2008, Pages 1003-1011

  Choong, Nicholas W ^a,b   Mauer, Ann M ^c   Haraf, Daniel J ^a,d   Lester, Eric ^e   Hoffman, Philip C ^a,d   Kozloff, Mark ^f   Lin, Shang ^g   Dancey, Janet E ^h   Szeto, Livia ^a   Grushko, Tatyana ^a,d   Olopade, Olufunmilayo I ^a,d   Salgia, Ravi ^a,d   Vokes, Everett E ^a,d,i  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c ADVOCATE ILLINOIS MASONIC MEDICAL CENTER   (United States)

^d University of Chicago   (United States)

^e Oncology Care Associates   (United States)

^f Ingalls Memorial Hospital   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ National Cancer Institute ^*  (United States)

Author keywords

Chemoradiotherapy; Epidermal growth factor inhibitor; Erlotinib; Multimodality therapy; Non small cell lung cancer

Indexed keywords

ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; ANTIINFLAMMATORY AGENT; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ERYTHROPOIETIN; ETOPOSIDE; FLUCONAZOLE; HEMOGLOBIN; PACLITAXEL; SUCRALFATE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TAXOID;

ACNE; ADD ON THERAPY; ADULT; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; ESOPHAGITIS; FATIGUE; FEMALE; FLUID THERAPY; FLUORESCENCE IN SITU HYBRIDIZATION; HEARING LOSS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; INOPERABLE CANCER; LARGE CELL CARCINOMA; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OTOTOXICITY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RASH; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; VOMITING; CANCER STAGING; GENE AMPLIFICATION; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REMISSION; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; ETOPOSIDE; FEMALE; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REMISSION INDUCTION; SURVIVAL RATE; TAXOIDS;

EID: 58149132003     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31818396a4     Document Type: Article

References (44)

1. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-530.
2. Zatloukal P, Petruzelka L, Zemanova M, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004;46:87-98.
3. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699.
4. Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003;22:Abstract 2499.
5. Vokes EE, Herndon JE II, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007;25:1698-1704.
6. Hanna NH, Neubauer M, Ansari R, et al. Phase III trial of cisplatin plus etoposide plus concurrent Chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small cell lung cancer: HOG LUN 01-24/USO-023. Proc Am Soc Clin Oncol 2007;25: Abstract 7512.
7. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-3807.
8. Suzuki S, Dobashi Y, Sakurai H, et al. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study. Cancer 2005;103:1265-1273.
9. Akimoto T, Hunter NR, Buchmiller L, et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999;5:2884-2890.
10. Bowers G, Reardon D, Hewitt T, et al. The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells. Oncogene 2001;20:1388-1397.
11. Contessa JN, Reardon DB, Todd D, et al. The inducible expression of dominant-negative epidermal growth factor receptor-CD533 results in radiosensitization of human mammary carcinoma cells. Clin Cancer Res 1999;5:405-411.
12. Sheridan MT, O'Dwyer T, Seymour CB, et al. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Investig 1997;5:180-186.
13. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, et al. Radiation-induced roliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 1997;15:1191-1197.
14. Harari PM, Huang SM. Modulation of molecular targets to enhance radiation. Clin Cancer Res 2000;6:323-325.
15. Huang SM, Li J, Armstrong EA, et al. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 2002;62:4300-4306.
16. Chinnaiyan P, Huang S, Vallabhaneni G, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005;65:3328-3335.
17. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the Head and Neck. N Engl J Med 2006; 354:567-578.
18. Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003; 21:2004-2010.
19. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353: 123-132.
20. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16:1425-1433.
21. Selvaggi G, Novello S, Torri V, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 2004;15:28-32.
22. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-655.
23. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005;353: 133-144.
24. Hanna N, Lilenbaum R, Ansari R, et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 2006;24:5253-5258.
25. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-3247.
26. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77-85.
27. Gordon AN, Finkler N, Edwards RP, et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 2005; 15:785-792.
28. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966.
29. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and pac-litaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899.
30. Rudin CM, Liu W, Desai A, et al. Pharmacogenomic and pharmacoki-netic determinants of erlotinib toxicity. J Clin Oncol 2008;26:1119-1127.
31. Wacker B, Nagrani T, Weinberg J, et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13:3913-3921.
32. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007;98:1817-1824.
33. Ready N, Janne P, Herndon J, et al. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer: a CALGB stratified phase II trial. Proc Am Soc Clin Oncol 2006;24:Abstract 7046.
34. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17.
35. Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001;92:1525-1530.
36. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-5909.
37. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib combined with cisplatin and gemcitabine chemotherapy in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2004;22: Abstract 7010.
38. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22:785-794.
39. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004;22:777-784.
40. Li T, Ling YH, Goldman ID, et al. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 2007;13:3413-3422.
41. Mahaffey CM, Davies AM, Lara PN Jr, et al. Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin Lung Cancer 2007;8:548-553.
42. Piperdi B, Ling YH, Kroog G, et al. Schedule-dependent interaction between epidermal growth factor inhibitors and G2/M blocking chemo-therapeutic agents on human NSCLC cell lines in vitro. Proc Am Soc Clin Oncol 2004;22:Abstract 7028.
43. Davies AM, Ho C, Lara PN Jr, et al. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer 2006;7:385-388.
44. Solit DB, She Y, Lobo J, et al. Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin Cancer Res 2005;11:1983-1989.